IP Library › Granted Patent US 12,247,084
Granted Patent B2
US 12,247,084 · App. 16/973,877 · Granted Mar 11, 2025

Anti-BCMA CAR antibodies, conjugates, and methods of use

Inventors: Kevin Friedman (Melrose, MA); Molly Reed Perkins (Milton, MA)
Assignee: 2seventy bio, Inc.
C07K16/4258C07K16/4241G01N33/56972G01N33/583C07K2317/21C07K2317/24C07K2317/34C07K2317/622G01N2333/70578
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,084
App. No.
16/973,877
Granted
Mar 11, 2025
Kind
B2
Abstract

The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.

Claims (14)

1. An antibody or antigen binding fragment thereof that binds an anti-BCMA scFv domain of an anti-BCMA CAR comprising a variable light chain comprising CDRL1-CDRL3 sequences set forth in SEQ ID NOs: 1-3 or 9-11; and a variable heavy chain comprising CDRH1-CDRH3 sequences set forth in SEQ ID NOs: 4-6 or 12-14.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof binds one or more epitopes of an anti-BCMA scFv sequence set forth in SEQ ID NO: 25.

3. The antibody or antigen binding fragment thereof of claim 1 , comprising a variable light chain sequence having 90% amino acid identity to an amino acid sequence as set forth in SEQ ID NO: 7 or 15.

4. The antibody or antigen binding fragment thereof of claim 1 , comprising a variable heavy chain sequence having 90% amino acid identity to an amino acid sequence as set forth in SEQ ID NO: 8, 16, or 24.

5. The antibody or antigen binding fragment thereof of claim 1 , comprising a variable light chain sequence having 90% amino acid identity to an amino acid sequence as set forth in SEQ ID NO: 7 or 15; and a variable heavy chain sequence having 90% amino acid identity to an amino acid sequence as set forth in SEQ ID NO: 8, 16, or 24.

6. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is murine, human, humanized, or chimeric.

7. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is monoclonal.

8. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a Fab′ fragments, F(ab′) 2 fragments, bispecific Fab dimers (Fab2), trispecific Fab trimers (Fab3), Fv, single chain Fv proteins (“scFv”), bis-scFv, (scFv) 2 , minibodies, diabodies, triabodies, tetrabodies, disulfide stabilized Fv proteins (“dsFv”), and single-domain antibody (sdAb).

9. A conjugate, comprising the antibody or antigen binding fragment thereof of claim 1 and a detectable label.

10. The conjugate of claim 9 , wherein the detectable label is selected from the group consisting of: a hapten, a fluorescent dye, a fluorescent protein, a chromophore, a metal ion, a gold particle, a silver particle, a magnetic particle, a polypeptide, an enzyme, a luminescent compound, or an oligonucleotide.

11. The conjugate of claim 9 , wherein the detectable label is a dye selected from the group consisting of: AF350, AF405, AF488, AF500, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710, AF750, AF790, and AF800.

12. The conjugate of claim 11 , wherein the detectable label is AF488.

13. A composition comprising the antibody or antigen-binding fragment thereof of claim 1 .

14. A kit comprising the antibody or antigen-binding fragment thereof of claim 1 , and instructions for use.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: BLUEBIRD BIO, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057683/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: FRIEDMAN, KEVIN; PERKINS, MOLLY REED
To: BLUEBIRD BIO, INC.
Reel/Frame 054916/0458 →
Continuity (2)
Provisional Application 62685043 · Jun 14, 2018
Related Publication 20210261689A1 · Aug 26, 2021
References Cited (60)
US 4671958A · Rodwell et al. · 1987 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5665357A · Rose et al. · 1997 [cited by applicant]
US 20160046724A1 · Brogdon · 2016 [cited by examiner]
US 20170051068A1 · Pillarisetti et al. · 2017 [cited by applicant]
US 20180162952A1 · Foord et al. · 2018 [cited by applicant]
US 20230030085A1 · Friedman et al. · 2023 [cited by applicant]
EP 0404097A2 · 1990 [cited by applicant]
WO WO1993001161A1 · 1993 [cited by applicant]
WO WO9306213A1 · 1993 [cited by applicant]
WO WO2012030982A1 · 2012 [cited by applicant]
WO WO2014190273A1 · 2014 [cited by applicant]
WO WO2016014565A2 · 2016 [cited by applicant]
WO WO2016014789A2 · 2016 [cited by applicant]
WO WO2016094304A2 · 2016 [cited by applicant]
WO WO2017031104A1 · 2017 [cited by applicant]
WO WO2018022786A1 · 2018 [cited by applicant]
WO WO2018156791A1 · 2018 [cited by applicant]
WO WO2018231759A1 · 2018 [cited by applicant]
WO WO2019161035A1 · 2019 [cited by applicant]
Bellucci, Roberto, et al. “Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.” Blood (2005); 105.10: 3945-3950. [cited by applicant]
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J Immunol. Jul. 1, 1991;147(1):86-95. [cited by applicant]
Borden and Kabat, “Nucleotide sequence of the cDNAs encoding the variable region heavy and light chains of a myeloma protein specific for the terminal nonreducing end of alpha(1-6)dextran”, Proc Natl Acad Sci U S A (198… [cited by applicant]
Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). [cited by applicant]
Bruggermann et al., “Designer mice: the production of human antibody repertoires in transgenic animals,” Year Immunol. 1993;7:33-40. [cited by applicant]
Chothia and Lesk, “Canonical structures for the hypervariable regions of immunoglobulins”, J Mol Biol (1987); 196(4):901-917. [cited by applicant]
Chothia, C. et al., “Conformations of immunoglobulin hypervariable regions”, Nature (1989); 342(6252):877-883. [cited by applicant]
Holliger, Philipp, et al. “Diabodies: small bivalent and bispecific antibody fragments.” Proceedings of the National Academy of Sciences (1993); 90.14: 6444-6448. [cited by applicant]
Holt, L. et al., “Domain antibodies: proteins for therapy”, Trends in Biotechnology (2003); 21(11):484-490. [cited by applicant]
Hudson, Peter J., and Souriau, Christelle. “Engineered antibodies.” Nature medicine 9.1 (2003): 129-134. [cited by applicant]
International Search Report and Written Opinion mailed on Oct. 1, 2019, for International Application No. PCT/US2019/037274, 8 pages. [cited by applicant]
Jakobovits et al., “Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production,” Proc Natl Acad Sci U S A. Mar. 15, 1993;90(6… [cited by applicant]
Jakobovits et al., “Germ-line transmission and expression of a human-derived yeast artificial chromosome,” Nature, 362: 255 (1993). [cited by applicant]
Kalled, “The role of BAFF in immune function and implications for autoimmunity,” Immunological Reviews, 2005, vol. 204: 43-54. [cited by applicant]
Kozbor et al., “A human hybrid myeloma for production of human monoclonal antibodies,” J Immunol. Dec. 1984;133(6):3001-5. [cited by applicant]
Laabi, Y., et al. “A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by at (4; 16)(q26; p13) translocation in a malignant T cell lymphoma.” The EMBO Journal (1992); 11.11: 3897-3904. [cited by applicant]
Laabi, Yacine, et al. “The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed.” Nucleic Acids Research (1994); 22.7: 1147-1154. [cited by applicant]
MacKay et al., “BAFF and April: A Tutorial on B Cell Survival,” Annu. Rev. Immunol., 2003, 21: 231-264. [cited by applicant]
Moreaux, Jérôme, et al. “BAFF and April protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.” Blood (2004); 103.8: 3148-3157. [cited by applicant]
Neri, Paola, et al. “Neutralizing B-Cell-Activating Factor Antibody Improves Survival and InhibitsOsteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model.” Clinical Cancer Research (2007); 1… [cited by applicant]
Ng et al., “B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells.” Journal of Immunology (2004); 173(2): 807-817. [cited by applicant]
Novak, Anne J., et al. “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.” Blood (2004); 103.2: 689-694. [cited by applicant]
O'Connor, Brian P., et al. “BCMA is essential for the survival of long-lived bone marrow plasma cells.” Journal of Experimental Medicine (2004); 199.1: 91-97. [cited by applicant]
Orlandi, R. et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction”, Proc Natl Acad Sci USA (1989); 86(10):3833-3737. [cited by applicant]
Plückthun, A. “Antibodies from [cited by applicant]
Schiemann, Barbara, et al. “An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.” Science (2001); 293.5537: 2111-2114. [cited by applicant]
Thompson et al., “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population,” J. Exp. Med., vol. 192, No. 1, Jul. 3, 2000,… [cited by applicant]
Whitelegg N & Rees AR, “WAM: an improved algorithm for modelling antibodies on the Web,” Protein Eng. Dec. 2000;13(12):819-24. [cited by applicant]
Whitelegg N & Rees AR, “Antibody variable regions: toward a unified modeling method,” Methods Mol Biol. 2004;248:51-91. [cited by applicant]
Wu and Kabat, “An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity”, J Exp Med. (1970); 132(2): 211-250. [cited by applicant]
Xu, Shengli, and Lam, Kong-Peng. “B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and April, is dispensable for humoral immune responses.” Molecular and Cellular Biology (2001); 21.1… [cited by applicant]
Conde et al., “Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine” Frontiers in Chemistry, Jul. 15, 2014, vol. 2, article 48, 27 pages. [cited by applicant]
Extended European Search Report for EP Application No. 19820088.3 dated Feb. 16, 2022, 9 pages. [cited by applicant]
Hu et al., “The Chimeric Antigen Receptor Detection Toolkit,” Frontiers in Immunology, Aug. 11, 2020, vol. 11, pp. 1-16. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/065352, dated Mar. 15, 2021, 10 pages. [cited by applicant]
Jena et al., “Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials”, PLoS One, vol. 8, No. 3, Mar. 1, 2013 (Mar. 1, 2013), p. e57838. [cited by applicant]
Reichman et al., “Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells,” International Journal of Molecular Sciences, Jan. 14, 2022, vol. 23, No. 2, 14 pages. [cited by applicant]
Smith et al., “Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CART Cell Vector,” Mol Ther. Jun. 6, 2018;26(6):1447-1456. [cited by applicant]
Supplementary European Search Report for European Application No. EP19820088.3, dated Mar. 9, 2022, 10 pages. [cited by applicant]
Extended European Search Report for EP Application No. 20902960.2 dated Mar. 7, 2024. [cited by applicant]
Cited By (1)
US 12,545,746